| ACT | adoptive cell transfer |
| AFP | alpha-fetoprotein |
| APC | antigen-presenting cell |
| CAF | cancer-associated fibroblast |
| CAR | chimeric antigen receptor |
| CD | cluster of differentiation |
| CI | confidence interval |
| CPI | checkpoint inhibition |
| CTL | cytotoxic lymphocyte |
| CTLA-4 | cytotoxic T lymphocyte antigen 4 |
| DC | dendritic cell |
| FDA | United States Food and Drug Administration |
| FOXP3 | forkhead box protein P3 |
| GM-CSF | granulocyte macrophage colony-stimulating factor |
| GPC3 | glypican-3 |
| HCC | hepatocellular carcinoma |
| HIF-1 | hypoxia-inducible factor 1 |
| HLA | human leukocyte antigen |
| hTERT | human telomerase reverse transcriptase |
| ICAM | intercellular adhesion molecule |
| IFN-γ | interferon gamma |
| IHC | immunohistochemistry |
| IL | interleukin |
| iNKT | invariant NK T cell |
| LAG-3 | lymphocyte-activation gene 3 |
| LAMP | lysosomal associated membrane protein |
| MAIT cell | mucosal-associated invariant T cell |
| MDSC | myeloid-derived suppressor cell |
| MHC | major histocompatibility complex |
| NAFLD | non-alcoholic fatty liver disease |
| NASH | non-alcoholic steatohepatitis |
| NY-ESO-1 | New York-esophageal squamous cell carcinoma-1 |
| ORR | objective response rate |
| OV | oncolytic virotherapy |
| PBMC | peripheral blood mononuclear cell |
| PD-1 | programmed cell death antigen 1 |
| PD-L1 | ligand for programmed cell death antigen 1 |
| Pexa-Vec | pexastimogene devacirepvec |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RFA | radiofrequency ablation |
| ROS | reactive oxygen species |
| SART | squamous cell carcinoma antigen recognized by T cells |
| SIRT | selective internal radiation therapy |
| TAA | tumor-associated antigen |
| TACE | transarterial chemoembolization |
| TAM | tumor-associated macrophage |
| TCGA | The Cancer Genome Atlas |
| TCR | T cell receptor |
| Teff | effector T cell |
| Tex | exhausted CD8 T cells |
| TGF-β | tumor growth factor beta |
| TIGIT | T cell immunoreceptor with Ig and ITIM domains |
| TIM-3 | T cell immunoglobulin and mucin domain containing protein 3 |
| TKI | tyrosine kinase inhibitor |
| TMB | tumor mutational burden |
| TME | tumor microenvironment |
| Tmem | memory T cell |
| Tregs | regulatory T cells |
| T-vec | talimogene laherparepvec |
| VCAM | vascular cell adhesion molecule |
| VEGF | vascular endothelial growth factor |
| VEGFR | vascular endothelial growth factor receptor. |